| Name | Title | Contact Details |
|---|
At SIS, were proud to be leaders in collecting, analyzing and distributing the deepest data sets and insights to professional sports teams across MLB, NBA and NFL, while also partnering extensively with the leagues themselves. Our mission is to enrich and optimize the decision-making process for sports teams, sportsbooks, and sports fans. Our vision is to create an unparalleled platform of sporting data and insights through best-in-class technology, products, and partnerships. Our versatility, subject matter expertise, and desire to enhance our partners performance is at the core of what we do. As we enter the next chapter of our trajectory, we are keen to put our data and newfound products to use to improve the sports fan experience, while being a critical part of the supply chain. Our existing database offers unparalleled detail and is updated daily, not just for the 3 professional sports listed, but at the collegiate, international and minor league levels as well. We are also moving further into the real-time data space (for the above noted sports) and into new sports/leagues. A key differentiator for us relative to competition is our flexibility and ability to customize feeds, data points, etc based on specific needs of partners. Company chairman John Dewan founded the company with a group of partners in 2003. John has been a pioneer in sports statistics for more than 40 years and was the founder of STATS Inc. In April of 2021, Audeo Capital announced a significant investment into SIS. Shortly thereafter, a new CEO (Dan Hannigan-Daley) and VP of Product/Engineering (Will Hester) joined the organization following years of success at DraftKings.
Autohuset Vestergaard A/S, Personvogne er blandt landets største bilvirksomheder. Vi har autoriseret salg af 11 bilmærker - Volvo, Polestar, Renault, KIA, Ford, Mazda, Dacia, Nissan, Maxus, JAC og BYD. Vi er repræsenteret med 12 filialer - Autohuset Vestergaard beskæftiger cirka 450 medarbejdere og sælger årligt mere end 15.000 nye og brugte biler. Vi er specialister inden for person- og varebiler til private og erhvervsdrivende. Autohuset Vestergaard skræddersyer en løsning, der matcher netop dit behov. Hvad end du ønsker at lease eller eje, så har vi løsningen til dig. Alle vores værksteder er ISO-certificerede og bemandet med top professionelle medarbejdere, der sikrer optimal pleje af din bil, uanset om det gælder service, reparation eller skadearbejde. Hos Autohuset Vestergaard er det vores målsætning, at skabe langsigtede relationer med vores kunder. I vores daglige arbejder bestræber vi os altid på at yde den indsats, der skal til, for at vi opnår yderst tilfredse kunder.
Cox PLLC exists to serve you and your company. We are litigators, counselors and trial attorneys. Our clients hire us to aggressively preserve or grow equity, eliminate risk and resolve disputes. We are available anytime and anywhere.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.